4,601 articles
Isatuximab
Isatuximab (Sarclisa, isatuximab-irfc) is a Sanofi anti-CD38 IgG1 monoclonal antibody for multiple myeloma, given with pomalidomide, carfilzomib, or VRd regimens; IV 10 mg/kg, subcutaneous 1,400 mg, efficacy similar to daratumumab.
Isaxonine
Isaxonine (2-(isopropylamino)pyrimidine, Nerfactor) is a withdrawn French neurotrophic drug for peripheral neuropathy, marketed 1981 as the phosphate salt and withdrawn in 1983-1984 for toxic hepatitis.
Islatravir
Islatravir (MK-8591, EFdA), Merck's nucleoside reverse transcriptase translocation inhibitor for HIV-1; 2021 FDA clinical holds over lymphocyte declines; approved 2026 as IDVYNSO with doravirine; once-weekly ISL/LEN in Phase 3.
ISM3091 / XL309 (USP1 inhibitor)
ISM3091, renamed XL309, is an oral USP1 inhibitor discovered by Insilico Medicine's Chemistry42 AI platform and licensed to Exelixis for $80 million upfront in 2023; it is in a Phase 1 solid tumor trial with olaparib.
Isocarboxazid
Isocarboxazid (Marplan) is an irreversible, non-selective hydrazine MAO-A/MAO-B inhibitor antidepressant marketed in 1959, dosed orally 10–60 mg daily, used for treatment-resistant depression with tyramine diet restrictions.
Isoconazole
Isoconazole (Travogen) is a racemic imidazole antifungal, CAS 27523-40-6, C18H14Cl4N2O, used as the nitrate in 1% creams and vaginal tablets; it inhibits fungal 14α-demethylase and treats dermatomycoses and vaginal candidiasis.
Isoetharine
Isoetharine (etyprenaline; Bronkosol, Bronkometer) is a discontinued, relatively selective beta-2 adrenergic agonist catecholamine bronchodilator for asthma, bronchitis, and emphysema, developed in 1934 at Hoechst and withdrawn from US marketing for non-safety reasons.
Isoniazid preventive therapy
Isoniazid preventive therapy is the administration of isoniazid, usually for 6 to 9 months, to people with latent tuberculosis infection to prevent progression to active TB disease.
Isopropamide
Isopropamide (isopropamide iodide, Darbid) is a long-acting quaternary ammonium antimuscarinic drug, first FDA-approved 1957, used orally for peptic ulcer and GI spasm; now discontinued for humans but retained in veterinary prochlorperazine combinations.
Isoxicam
Isoxicam (Maxicam, W 8495) is a withdrawn oxicam NSAID, a piroxicam analog dosed 200 mg once daily for arthritis, suspended worldwide in October 1985 after fatal Stevens-Johnson syndrome and toxic epidermal necrolysis cases.
Istevir hydrochloride (AI-assisted COVID-19 drug)
Iscartrelvir hydrochloride (盐酸伊司特韦片, trade name 艾普司韦, codes WPV01/WU-04) is an oral SARS-CoV-2 3CLpro inhibitor for adult mild/moderate COVID-19, conditionally approved by China's NMPA in July 2026 as a Class 1 innovative drug, the first AI-assisted original drug approved in China and first DEL-derived approved small molecule.
Istradefylline
Istradefylline (NOURIAST, Nourianz; KW-6002) is a first-in-class adenosine A2A receptor antagonist taken once daily with levodopa for OFF episodes in Parkinson's disease; approved in Japan 2013 and by the FDA in 2019.
Isunakinra
Isunakinra (formerly EBI-005) is a recombinant fusion protein that blocks interleukin-1 signaling, developed by Eleven Biotherapeutics as an eye-drop treatment for dry eye disease and allergic conjunctivitis.
Itacitinib
Itacitinib (INCB039110), an oral JAK1-selective inhibitor from Incyte, was tested in psoriasis, rheumatoid arthritis, myelofibrosis, and GVHD; its pivotal phase 3 acute GVHD trial (GRAVITAS-301) failed its primary endpoint.
Itepekimab
Itepekimab (REGN3500, SAR440340) is a fully human anti-IL-33 IgG4P monoclonal antibody from Sanofi and Regeneron for COPD, asthma, and rhinosinusitis; AERIFY-1 met its endpoint, AERIFY-2 did not.
Itolizumab
Itolizumab (T1h, EQ001, ALZUMAb) is a humanized anti-CD6 IgG1 monoclonal antibody that blocks CD6-ALCAM T-cell co-stimulation. Approved in India in 2013 for plaque psoriasis and given emergency use authorization in 2020 for COVID-19 cytokine release syndrome.
Itopride
Itopride (Ganaton) is a benzamide gastroprokinetic combining dopamine D2 antagonism and acetylcholinesterase inhibition, metabolized by flavin-containing monooxygenase, used for functional dyspepsia with modest pooled efficacy and no QT prolongation.
Itraconazole
Itraconazole (Sporanox, SUBA-itraconazole) is a Janssen-discovered triazole antifungal inhibiting fungal 14-alpha-demethylase; used for histoplasmosis, blastomycosis, aspergillosis, and onychomycosis, with CYP3A4 interactions and TDM.
Ivabradine
Ivabradine (Corlanor, Procoralan) is a selective HCN/I_f channel blocker that slows the sinus node without affecting blood pressure or contractility. Approved for HFrEF (LVEF ≤35%, HR ≥70 bpm) and pediatric dilated cardiomyopathy; SHIFT showed fewer heart-failure hospitalizations, no mortality benefit.
Ivarmacitinib
Ivarmacitinib (艾玛昔替尼, SHR0302, brand Asuda) is an oral selective JAK1 inhibitor by Jiangsu Hengrui, first approved in China in 2025 for rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and alopecia areata.
Ivermectin
Ivermectin, also sold as Stromectol, Mectizan, and Ivomec, is a broad-spectrum avermectin-class antiparasitic drug used against roundworms, mites, and lice; developers Campbell and Ōmura shared the 2015 Nobel Prize.
Ivonescimab (AK112)
Ivonescimab (依沃西单抗, AK112/SMT112) is Akeso's first-in-class tetravalent Fc-silent bispecific antibody blocking PD-1 and VEGF, licensed to Summit Therapeutics for up to $5 billion; approved in China for NSCLC, with HARMONi-2 beating pembrolizumab on PFS and OS.
Ivuxolimab
Ivuxolimab (PF-04518600, PF-8600), Pfizer's fully human IgG2 agonistic anti-OX40 (CD134) monoclonal antibody for cancer immunotherapy; phase I trials showed no DLTs, 5.8% partial responses, and combination data with utomilumab.
Ixabepilone
Ixabepilone (Ixempra, BMS-247550, aza-epothilone B) is a semisynthetic epothilone B lactam microtubule inhibitor, first FDA-approved in October 2007 for anthracycline- and taxane-resistant metastatic or locally advanced breast cancer.
Ixazomib
Ixazomib (Ninlaro) is the first oral proteasome inhibitor, approved in 2016 with lenalidomide and dexamethasone for relapsed multiple myeloma after one prior therapy; TOURMALINE-MM1 improved PFS but not overall survival.
IxCell human umbilical cord MSC injection (hUC-MSC-O)
IxCell hUC-MSC-O is an allogeneic human umbilical cord mesenchymal stem cell injection for knee osteoarthritis by Shanghai Ixcell Biopharmaceutical, licensed for clinical trials in China in 2019.
Ixekizumab
Ixekizumab (Taltz), Eli Lilly's humanized IgG4 monoclonal antibody against interleukin-17A, injected subcutaneously for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis; first FDA-approved March 22, 2016.
Ixiaro
Ixiaro (JESPECT) is Valneva's inactivated Vero cell culture-derived Japanese encephalitis vaccine, the only JE vaccine licensed in the United States, approved 2009 for adults and 2013 for children aged 2 months and older, given as two doses.
Izalontamab
Izalontamab (SI-B001) is an experimental bispecific antibody that targets EGFR and HER3 on cancer cells to block tumor growth; it also serves as the targeting part of izalontamab brengitecan, an antibody-drug conjugate.
Izalontamab brengitecan
Izalontamab brengitecan (伦康依隆妥单抗, iza-bren, BL-B01D1, BMS-986507) is a first-in-class EGFR×HER3 bispecific antibody-drug conjugate with a topoisomerase I inhibitor payload, approved in China in 2026 for nasopharyngeal and esophageal cancers.